Abstract
Immunotherapy has changed the landscape of cancer treatment, and the immune checkpoint inhibitor pembrolizumab is now approved for the treatment of advanced and early-stage triple-negative breast cancer. Selection of patients for immunotherapy is evolving—PD-L1 status predicts immunotherapy benefit in the metastatic setting, but no biomarker has emerged as predictive in early-stage disease. The landscape of immunotherapy in breast cancer is rapidly advancing, and a number of immunotherapeutic strategies are under investigation. These include novel immune checkpoint targets, combinations of immunotherapy with immunomodulatory chemotherapy or small-molecule inhibitors, injectable agents directly altering the immune microenvironment, and cellular therapies. These strategies hold promise to improve the efficacy and scope of immunotherapy in breast cancer, with the ultimate goal of curing more patients of disease and prolonging survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Bland and Copeland's The Breast: Comprehensive Management of Benign and Malignant Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
